5th generation glp-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease GLP-1 Agonists: A Comprehensive Overview

Visit the website, select your dosage and pharmacy, and save or print the card to show your pharmacist

Pertea, G

Endocrinology Targeting the central melanocortin system for the treatment of metabolic disorders 2023 DOI: 10.1038/s41574-023-00855-y PMID: 37365323 Sweeney P, Gimenez LE, Hernandez CC, et al

Results Patient characteristics Thirty seven patients completed baseline scanning

A 2026 UK review of standardised EGb 761 , the Laws 2012 healthy-adult meta-analysis showing no effect, the null GEM and GuidAge trials, the modest mild-dementia benefit, dosing and the bleeding risk versus Dihexas unproven HGF/c-Met synaptogenesis and the c-Met concern

Our Hormone Transitions and Longevity Medicine page provides additional context